PR Newswire
EMERYVILLE, Calif.
, Feb. 25, 2025 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences:
- TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11 at 10:00 a.m. ET
The presentations will be webcast and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.
For Investors/Media:
Paul Cox
[email protected]
510-665-0499
Nicole Arndt
[email protected]
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-upcoming-investor-conferences-302385222.html
SOURCE Dynavax Technologies
